RU2002122335A - Азотсодержащее циклическое соединение и фармацевтическая композиция, включающая указанное соединение - Google Patents
Азотсодержащее циклическое соединение и фармацевтическая композиция, включающая указанное соединениеInfo
- Publication number
- RU2002122335A RU2002122335A RU2002122335/04A RU2002122335A RU2002122335A RU 2002122335 A RU2002122335 A RU 2002122335A RU 2002122335/04 A RU2002122335/04 A RU 2002122335/04A RU 2002122335 A RU2002122335 A RU 2002122335A RU 2002122335 A RU2002122335 A RU 2002122335A
- Authority
- RU
- Russia
- Prior art keywords
- group
- substituted
- ring
- cyano
- hydrate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 37
- -1 Nitrogen-containing cyclic compound Chemical class 0.000 title claims 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 41
- 150000003839 salts Chemical class 0.000 claims abstract 34
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 27
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract 15
- 210000002569 neuron Anatomy 0.000 claims abstract 13
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 11
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract 10
- 125000002252 acyl group Chemical group 0.000 claims abstract 9
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims abstract 6
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 5
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000008485 antagonism Effects 0.000 claims abstract 4
- 239000011575 calcium Substances 0.000 claims abstract 4
- 229910052791 calcium Inorganic materials 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 125000002947 alkylene group Chemical group 0.000 claims abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract 2
- 229930192474 thiophene Natural products 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 125000002560 nitrile group Chemical group 0.000 claims 17
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 10
- 210000004556 brain Anatomy 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 150000004945 aromatic hydrocarbons Chemical group 0.000 claims 7
- 206010008118 cerebral infarction Diseases 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 5
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000000480 calcium channel blocker Substances 0.000 claims 4
- 230000030833 cell death Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- GVDUKPVDFXGFEM-UHFFFAOYSA-N 5-[3-cyano-6-[4-[2-(3-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(F)=C1 GVDUKPVDFXGFEM-UHFFFAOYSA-N 0.000 claims 3
- UZNNCHDSFCJLGM-UHFFFAOYSA-N 5-[3-cyano-6-[4-[2-(4-fluorophenoxy)ethyl]piperazin-1-yl]-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound C=1C=C(C#N)SC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=C(F)C=C1 UZNNCHDSFCJLGM-UHFFFAOYSA-N 0.000 claims 3
- XCLNZZVJSMBOIO-UHFFFAOYSA-N 5-[4-[2-(3-fluorophenoxy)ethyl]piperazin-1-yl]-2-propan-2-yl-2-thiophen-2-ylpentanenitrile Chemical compound C=1C=CSC=1C(C(C)C)(C#N)CCCN(CC1)CCN1CCOC1=CC=CC(F)=C1 XCLNZZVJSMBOIO-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- 206010048962 Brain oedema Diseases 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 3
- 206010019196 Head injury Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 108090000699 N-Type Calcium Channels Proteins 0.000 claims 3
- 102000004129 N-Type Calcium Channels Human genes 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 208000028683 bipolar I disease Diseases 0.000 claims 3
- 208000006752 brain edema Diseases 0.000 claims 3
- 230000003925 brain function Effects 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 230000003412 degenerative effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 2
- AVGHIQUXSVAJBC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.1]heptane Chemical group C1C2CCN1NC2 AVGHIQUXSVAJBC-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 108090000312 Calcium Channels Proteins 0.000 claims 2
- 102000003922 Calcium Channels Human genes 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 108010027023 Q-Type Calcium Channels Proteins 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000034994 death Effects 0.000 claims 2
- 150000002430 hydrocarbons Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000005936 piperidyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- XVNCXOLDKUMQME-UHFFFAOYSA-N 1-[1-(4-cyano-5-methyl-4-phenylhexyl)piperidin-4-yl]-4-phenylpiperidine-4-carbonitrile Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN(CC1)CCC1N(CC1)CCC1(C#N)C1=CC=CC=C1 XVNCXOLDKUMQME-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- SMANTNBDDJUWPC-UHFFFAOYSA-N 2-phenyl-5-[4-(4-phenylpiperidin-1-yl)piperidin-1-yl]-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN(CC1)CCC1N(CC1)CCC1C1=CC=CC=C1 SMANTNBDDJUWPC-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- SNSVQLSICUJSNU-UHFFFAOYSA-N 5-[4-(1-ethylbenzimidazol-2-yl)-1,4-diazepan-1-yl]-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound N=1C2=CC=CC=C2N(CC)C=1N(CC1)CCCN1CCCC(C#N)(C(C)C)C1=CC=CC=C1 SNSVQLSICUJSNU-UHFFFAOYSA-N 0.000 claims 1
- GYXYNOBAELFHPV-UHFFFAOYSA-N 5-[4-(1-methylbenzimidazol-2-yl)-1,4-diazepan-1-yl]-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound C1CCN(C=2N(C3=CC=CC=C3N=2)C)CCN1CCCC(C(C)C)(C#N)C1=CC=CC=C1 GYXYNOBAELFHPV-UHFFFAOYSA-N 0.000 claims 1
- UVXYSYRGBVLXSK-UHFFFAOYSA-N 5-[4-(4-benzylpiperidin-1-yl)piperidin-1-yl]-2-phenyl-2-propan-2-ylpentanenitrile Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN(CC1)CCC1N(CC1)CCC1CC1=CC=CC=C1 UVXYSYRGBVLXSK-UHFFFAOYSA-N 0.000 claims 1
- GWOWLSFGWWZDOM-DXDQHDRFSA-N 5-[6-[(3r)-3-[benzyl(2-cyanoethyl)amino]pyrrolidin-1-yl]-3-cyano-2-methylhexan-3-yl]thiophene-2-carbonitrile Chemical compound N#CCCN([C@@H]1CCN(C1)CCCC(C(C)C)(C#N)C=1SC(=CC=1)C#N)CC1=CC=CC=C1 GWOWLSFGWWZDOM-DXDQHDRFSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 108700012358 P/Q-type calcium channel Proteins 0.000 claims 1
- 102000050761 P/Q-type calcium channel Human genes 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical group C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 229940125400 channel inhibitor Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- GKPOOPJSMDBBND-UHFFFAOYSA-N ethyl 4-(4-cyano-5-methyl-4-phenylhexyl)-1-[2-(4-fluorophenoxy)ethyl]piperazine-2-carboxylate Chemical compound C1CN(CCOC=2C=CC(F)=CC=2)C(C(=O)OCC)CN1CCCC(C#N)(C(C)C)C1=CC=CC=C1 GKPOOPJSMDBBND-UHFFFAOYSA-N 0.000 claims 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (43)
1. Соединение формулы (I), его соль или гидрат
где в указанной формуле Ar означает (1) С6-14 ароматическую углеводородную циклическую группу, которая может быть замещена, (2) 5-14-членную ароматическую гетероциклическую группу, которая может быть замещена, (3) C1-6 алкильную группу, замещенную C6-14 ароматической углеводородной циклической группой, которая может быть замещена, или (4) C1-6 алкильную группу, замещенную 5-14-членной ароматической гетероциклической группой, которая может быть замещена;
кольцо А представляет соответственно пиперазиновое кольцо, гомопиперазиновое кольцо, пиперидиновое кольцо, гомопиперидиновое кольцо, пирролидиновое кольцо или диазабицикло[2,2,1]гептановое кольцо, которые, соответственно, могут быть замещены;
кольцо В представляет (1) С3-14 углеводородное кольцо, которое может быть замещено, или (2) 5-14-членное гетероциклическое кольцо, которое может быть замещено;
Е означает (1) простую связь, группу формулы (2) -СО- или (3) -СН(ОН)-;
Х означает (1) простую связь, (2) атом кислорода, (3) атом серы, (4) C1-6 алкиленовую цепь, которая может быть замещена, группу формулы (5) -NR2- (где R2 означает атом водорода или C1-6 алкильную группу, С3-8 циклоалкильную группу, низшую ацильную группу или C1-6 алкилсульфонильную группу, которые могут быть замещены), (6) -СО-, (7) -COO-, (8) -ООС-, (9) -CONR3- (где R3 означает атом водорода или C1-6 алкильную группу, которые могут быть замещены), (10) -NR4CO- (где R4 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (11) -SO-, (12) -SO2-, (13) -SONR5- (где R5 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (14) -NR6SO- (где R6 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (15) -SO2NR7 (где R7 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (16) -NR8SO2- (где R8 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (17) >C=N-OR9 (где R9 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (18) -NR10W3-O- (где R10 означает атом водорода или C1-6 алкильную группу, С3-8 циклоалкильную группу, низшую ацильную группу или C1-6 алкилсульфонильную группу, которая может быть замещена; и W3 означает C1-6 алкиленовую группу, которая может быть замещена), (19) -NH-CO-NH-, (20) -NH-CS-NH-, (21) -C(=NR15)NR16- (где R15 и R16 имеют одинаковые или разные значения и представляют атом водорода, нитрильную группу, C1-6 алкильную группу, С2-6 алкенильную группу, С3-8 циклоалкильную группу или С3-8 циклоалкенильную группу), (22) -NHC(=NH)-, (23) -O-CO-S-, (24) -S-CO-O-, (25) -ОСОО-, (26) -NHCOO-, (27) -OCONH-, (28) -CO(CH2)mO- (где m означает 0 или целое число от 1 до 6), (29) -СНОН- или (30) -СНОН (СН2)nО- (где n означает 0 или целое число от 1 до 6); R1 означает (1) атом водорода, (2) атом галогена, (3) гидроксильную группу, (4) C1-6 алкильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и нитрильной группы, (5) C2-6 алкенильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и нитрильной группы, (6) C2-6 алкинильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и нитрильной группы, (7) С3-8 циклоалкильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и нитрильной группы, (9) C1-6 алкокси-C1-6 алкильную группу, (10) амино-C1-6 алкильную группу, в которой атом азота может быть замещен, (11) группу формулы -N(R11)R12- (где R11 и R12 имеют одинаковые или разные значения и представляют, каждый, атом водорода или C1-6 алкильную группу), (12) аралкильную группу, (13) морфолинильную группу, (14) тиоморфолинильную группу, (15) пиперидильную группу, (16) пирролидинильную группу или (17) пиперазинильную группу; и
D1, D1, W1 и W2 имеют одинаковые или разные значения и представляют (1) простую связь или (2) C1-6 алкиленовую цепь, которая может быть замещена;
при условии, что из приведенного выше определения исключены 1-[4-циано-5-метил-4-(2-циано-5-тиенил)гексил]-4-[2-(4-фторфенокси)этил]пиперазин; 1-[4-циано-5-метил-4-(2-циано-5-тиенил)гексил]-4-[2-(3-фторфенокси)этил]пиперазин и 1-[4-циано-5-метил-4-(2-тиенил)гексил]-4-[2-(3-фторфенокси)этил]пиперазин.
2. Соединение по п.1, его соль или гидрат, где Ar означает C6-14 ароматическое углеводородное кольцо или 5-14-членное ароматическое гетероциклическое кольцо, которое может быть замещено.
3. Соединение по п.1, его соль или гидрат, где Ar означает тиофеновое кольцо или бензольное кольцо, которое может быть замещено.
4. Соединение по п.1, его соль или гидрат, где Ar означает С6-14 ароматическое углеводородное кольцо или 5-14-членное ароматическое углеводородное кольцо, которое может быть замещено одной или несколькими группами, выбираемыми из нитрильной группы и атома галогена.
5. Соединение по п.1, его соль или гидрат, где Ar означает тиофеновое кольцо или бензольное кольцо, которое может быть замещено одной или несколькими группами, выбираемыми, соответственно, из нитрильной группы и атома галогена.
6. Соединение по п.1, его соль или гидрат, где кольцо А представляет собой пиперазиновое кольцо, гомопиперазиновое кольцо или пиперидиновое кольцо.
7. Соединение по п.1, его соль или гидрат, где кольцо А представляет пиперазиновое кольцо.
8. Соединение по п.1, его соль или гидрат, где кольцо А представляет пиперазиновое кольцо, гомопиперазиновое кольцо или пиперидиновое кольцо, которое может быть замещено одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена, цианогруппы, C1-6 алкильной группы, которая может быть замещена, С2-6 алкенильной группы, которая может быть замещена, C2-6 алкинильной группы, которая может быть замещена, C1-6 алкоксильной группы, которая может быть замещена, C2-6 алкенилоксигруппы, которая может быть замещена, C1-6 алкилкарбонильной группы, которая может быть замещена, C2-6 алкенилкарбонильной группы, которая может быть замещена, C1-6 алкоксикарбонильной группы, которая может быть замещена, и С2-6 алкенилоксикарбонильной группы, которая может быть замещена.
9. Соединение по п.1, его соль или гидрат, где кольцо В представляет С6-14 ароматическое углеводородное кольцо или 5-14-членное ароматическое гетероциклическое кольцо, которые, соответственно, могут быть замещены.
10. Соединение по п.1, его соль или гидрат, где кольцо В представляет бензол, тиофен, пиридин, 1,4-бензодиоксан, индол, бензотиазол, бензоксазол, бензимидазол, 2-кето-1-бензимидазол, тиазол, оксазол, изоксазол, 1,2,4-оксадиазол, инданон, бензофуран, хинолин, 1,2,3,4-тетрагидрохинолин, нафталин или 1,2,3,4-тетрагидронафталин, которые, соответственно, могут быть замещены.
11. Соединение по п.1, его соль или гидрат, где кольцо В представляет С6-14 ароматическое углеводородное кольцо или 5-14-членное ароматическое гетероциклическое кольцо, которые, соответственно, могут быть замещены одной или несколькими группами, выбираемыми из атома галогена, нитрильной группы, C1-6 алкильной группы, низшей ацильной группы, C1-6 алкилсульфонильной группы и аралкильной группы.
12. Соединение по п.1, его соль или гидрат, где D1 и D2 имеют одинаковые или разные значения и представляют (1) простую связь или (2) C1-6 алкиленовую цепь, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена, нитрильной группы, C1-6 алкильной группы, C2-6 алкенильной группы и C1-6 алкоксильной группы.
13. Соединение по п.1, его соль или гидрат, где Е означает простую связь.
14. Соединение по п.1, его соль или гидрат, где D1 и D2 означают C1-6 алкиленовую цепь и Е означает простую связь.
15. Соединение по п.1, его соль или гидрат, где частичная структура -D1-E-D2- представляет C1-4 алкиленовую группу.
16. Соединение по п.1, его соль или гидрат, где W1 и W2 имеют одинаковые или разные значения и представляют, каждый, (1) простую связь или (2) C1-6 алкиленовую цепь, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена, нитрильной группы, C1-6 алкилоксигруппы и С2-6 алкенилоксигруппы.
17. Соединение по п.1, его соль или гидрат, где W1 означает (1) простую связь или (2) C1-6 алкиленовую цепь, которая может быть замещена одной или несколькими группами, выбираемыми из (i) нитрильной группы, (ii) C1-6 алкильной группы, которая может быть замещена одной или несколькими группами, выбираемыми из C1-6 алкоксильной группы и С2-6 алкенилоксигруппы, и (iii) С2-6 алкенильной группы; и W2 означает простую связь.
18. Соединение по п.1, его соль или гидрат, где W1 и W2 имеют одинаковые или разные значения и представляют, каждый, C1-6 алкиленовую цепь, замещенную одной или несколькими группами, выбираемыми из C1-6 алкильной группы и С2-6 алкенильной группы, причем вышеуказанные C1-6 алкильная группа и/или С2-6 алкенильная группа могут быть связаны друг с другом с образованием кольца либо вышеуказанная C1-6 алкильная группа или С2-6 алкенильная группа может быть связана с кольцом В или Х с образованием кольца.
19. Соединение по п.1, его соль или гидрат, где Х означает (1) простую связь, (2) атом кислорода, группу формулы (3) -NR2- (где R2 означает атом водорода, C1-6 алкильную группу, С3-8 циклоалкильную группу, низшую ацильную группу или C1-6 алкилсульфонильную группу, которые могут быть замещены), (4) -NR10-W3-O- (где R10 означает атом водорода, C1-6 алкильную группу, С3-8 циклоалкильную группу, низшую ацильную группу или C1-6 алкилсульфонильную группу, которые могут быть замещены; и W3 означает C1-6 алкиленовую группу, которая может быть замещена) или (5) -NH-SO2-.
20. Соединение по п.1, его соль или гидрат, где Х означает (1) атом кислорода, группу формулы (2) -NR2- (где R2 означает атом водорода, C1-6 алкильную группу, С3-8 циклоалкильную группу, низшую ацильную группу или C1-6 алкилсульфонильную группу, которая может быть замещена) или (3) -NH-SO2-.
21. Соединение по п.1, его соль или гидрат, где частичная структура -W1-X-W2- представляет C1-6 алкиленовую группу, которая может быть замещена.
22. Соединение по п.1, его соль или гидрат, где W1 означает C1-6 алкиленовую цепь, которая может быть замещена; W2 означает простую связь; и Х означает кислород или группу формулы -NR2- (где R2 имеет указанные выше значения).
23. Соединение по п. 22, его соль или гидрат, где заместитель W1 представляет одну или несколько групп, выбираемых из (1) нитрильной группы, (2) C1-6 алкильной группы, которая может быть замещена C1-6 алкилоксигруппой или С2-6 алкенилоксигруппой, и (3) С2-6 алкенильной группы; и R2 означает C1-6 алкильную группу, которая может быть замещена.
24. Соединение по п.1, его соль или гидрат, где R1 означает C1-6 алкильную группу.
25. Соединение по п.1, его соль или гидрат, где R1 означает метильную, этильную, н-пропильную или изопропильную группу.
26. Соединение формулы (II), его соль или гидрат
где в указанной формуле R1 имеет приведенные выше значения;
R13 и R14 имеют одинаковые или разные значения и представляют (1) атом водорода, (2) атом галогена, (3) гидроксильную группу, (4) меркаптогруппу, 5) C1-6 алкильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы и атома галогена, (6) C1-6 алкоксильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и C1-6 алкоксикарбонильной группы, (7) нитрогруппу, (8) аминогруппу, которая может быть замещена, (9) цианогруппу, (10) карбоксильную группу, (11) C1-6 алкоксикарбонильную группу, (12) C1-6 тиоалкоксильную группу, (13) C1-6 алкилсульфонильную группу, (14) низшую ацильную группу, (15) С6-14 ароматическую углеводородную циклическую группу, которая может быть замещена, (16) 5-14-членную ароматическую гетероциклическую группу, которая может быть необязательно замещена, (17) арилоксигруппу или (18) аралкилоксигруппу либо (19) все вместе элементы R13 или все вместе элементы R14 связаны друг с другом с образованием (i) алифатического кольца, которое может быть замещено, (ii) гетероциклического кольца, которое может быть замещено, или (iii) алкилендиоксигруппы;
n означает 0 или целое число от 1 до 3;
р означает целое число от 1 до 6;
q означает целое число от 1 до 6; и
r означает 0 или целое число от 1 до 5;
при условии, что из приведенного выше определения исключены 1-[4-циано-5-метил-4-(2-циано-5-тиенил)гексил]-4-[2-(4-фторфенокси)этил]пиперазин; 1-[4-циано-5-метил-4-(2-циано-5-тиенил)гексил]-4-[2-(3-фторфенокси)этил]пиперазин и 1-[4-циано-5-метил-4-(2-тиенил)гексил]-4-[2-(3-фторфенокси)этил]пиперазин.
27. Соединение формулы (III), его соль или гидрат
где в указанной формуле R1 и R2 имеют приведенные выше значения;
R13 и R14 имеют одинаковые или разные значения и представляют (1) атом водорода, (2) атом галогена, (3) гидроксильную группу, (4) меркаптогруппу, (5) C1-6 алкильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы и атома галогена, (6) C1-6 алкоксильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и C1-6 алкоксикарбонильной группы, (7) нитрогруппу, (8) аминогруппу, которая может быть замещена, (9) цианогруппу, (10) карбоксильную группу, (11) C1-6 алкоксикарбонильную группу, (12) C1-6 тиоалкоксильную группу, (13) C1-6 алкилсульфонильную группу, (14) низшую ацильную группу, (15) С6-14 ароматическую углеводородную циклическую группу, которая может быть замещена, (16) 5-14-членную ароматическую гетероциклическую группу, которая может быть замещена, (17) арилоксигруппу, (18) аралкилоксигруппу или (19) все вместе элементы R13 или все вместе элементы R14 могут быть связаны друг с другом с образованием (i) алифатического кольца, которое может быть замещено, (ii) гетероциклического кольца, которое может быть замещено, или (iii) алкилендиоксигруппы;
n означает 0 или целое число от 1 до 3;
р означает целое число от 1 до 6;
q означает целое число от 1 до 6;
r означает 0 или целое число от 1 до 5.
28. Соединение по п.1, его соль или гидрат, которое выбирают из группы, включающей
4-[(4-циано-5-метил-4-фенил)гексил]-N-(4-фторфенил)-N’-(2-метилпропил)-1(2Н)-пиразинкарбоксиимидамид,
1-изопропил-4-[4-(1-изобутил-1Н-бензо[d]имидазол-2-ил)пиперазино]-1-фенилбутилцианид,
1-[4-циано-5-метил-4-(5-циано-2-тиенил)гексил]-4-[2-(3-цианофенокси)этил]пиперазин,
1-[4-циано-5-метил-4-(2-тиенил)гексил]-4-[2-(3-цианофенокси)этил]пиперазин,
1-[4-циано-5-метил-4-(5-циано-2-тиенил)гексил]-4-[3-(5-циано-2-тиенил)пропил]пиперазин,
1-[4-циано-5-метил-4-(3-тиенил)гексил]-4-[2-(3-цианофенокси)этил]пиперазин,
1-{4-циано-5-метил-4-[4-(2-циано)тиенил]гексил}-4-[2-(3-цианофенокси)этил]пиперазин,
1-[(4-циано-5-метил-4-фенил)гексил]-4-[(2-бензоксазолил)амино]пиперидин,
1-[4-циано-4-(5-циано-2-тиенил)-5-метилгексил]-(3S)-3-[N-(2-цианоэтил)-N-бензиламино]пирролидин,
1-[4-циано-4-(5-циано-2-тиенил)-5-метилгексил]-(3R)-3-[N-(2-цианоэтил)-N-бензиламино]пирролидин,
1-[(4-циано-5-метил-4-фенил)гексил]-4-(бензотиазолил]пиперазин,
1-[(4-циано-5-метил-4-фенил)гексил]-4-[2-(6-метокси)бензотиазолил]пиперазин,
1-[(4-циано-5-метил-4-фенил)гексил]-4-(2-бензоксазолил)пиперазин,
1-[(4-циано-5-метил-4-фенил)гексил]-4-(2-хинолинил)пиперазин,
4-[4-(1-метил-1Н-бензо[d]имидазол-2-ил)-1,4-диазепан-1-ил]-1-изопропил-1-фенилбутилцианид,
4-[4-(1-этил-1Н-бензо[d]имидазол-2-ил)-1,4-диазепан-1-ил]-1-изопропил-1-фенилбутилцианид,
этил-4-(4-циано-5-метил-4-фенилгексил)-1-[2-(4-фторфенокси)этил]-2-пиперазинкарбоксилат,
1-[(2-оксо-1,2-дигидро-3-хинолил)метил]-4-[(4-циано-5-метил-4-фенил)гексил]пиперидин,
4-[(4-циано-5-метил-4-фенил)гексил]-1-{[2-(метансульфониламино)фенил]метил}пиперазин,
4-[(4-циано-5-метил-4-фенил)гексил]-1-{[2-(метансульфониламино)фенил]метил}пиперидин,
{1-[4-циано-5-метил-5-(2-тионил)гексил]пиперазинил}амид(S)-3-фенил-2-аминопропановой кислоты,
4-[4-(4-фенилпиперидинил)пиперидинил]-1-изопропил-1-фенилбутилцианид,
4-[4-(4-циано-4-фенилпиперидинил)пиперидинил]-1-изопропил-1-фенилбутилцианид, и
4-[4-(4-бензилпиперидинил)пиперидинил]-1-изопропил-1-фенилбутилцианид.
29. Фармацевтическая композиция, содержащая соединение формулы (I), его соль или гидрат
где в указанной формуле Ar означает (1) С6-14 ароматическую углеводородную циклическую группу, которая может быть замещена, (2) 5-14-членную ароматическую гетероциклическую группу, которая может быть замещена, (3) C1-6 алкильную группу, замещенную C6-14 ароматической углеводородной циклической группой, которая может быть замещена, или (4) C1-6 алкильную группу, замещенную 5-14-членной ароматической гетероциклической группой, которая может быть замещена;
кольцо А представляет пиперазиновое кольцо, гомопиперазиновое кольцо, пиперидиновое кольцо, гомопиперидиновое кольцо, пирролидиновое кольцо или диазабицикло[2,2,1]гептановое кольцо, которые, соответственно, могут быть замещены;
кольцо В представляет (1) С3-14 углеводородное кольцо, которое может быть замещено, или (2) 5-14-членное гетероциклическое кольцо, которое может быть замещено;
Е означает (1) простую связь, группу формулы (2) -СО- или (3) -СН(ОН)-;
Х означает (1) простую связь, (2) атом кислорода, (3) атом серы, (4) C1-6 алкиленовую цепь, которая может быть замещена, группу формулы (5) -NR2- (где R2 означает атом водорода или C1-6 алкильную группу, С3-8 циклоалкильную группу, низшую ацильную группу или C1-6 алкилсульфонильную группу, которые могут быть замещены), (6) -СО-, (7) -COO-, (8) -ООС-, (9) -CONR3- (где R3 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (10) -NR4CO-(где R4 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (11) -SO-, (12) -SO2-, (13) -SONR5- (где R5 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (14) -NR6SO- (где R6 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (15) -SO2NR7- (где R7 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (16) -NR8SO2- (где R8 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (17) >C=N-OR9 (где R9 означает атом водорода или C1-6 алкильную группу, которая может быть замещена), (18) -NR10W3-O- (где R10 означает атом водорода или C1-6 алкильную группу, С3-8 циклоалкильную группу, низшую ацильную группу или C1-6 алкилсульфонильную группу, которые могут быть замещены; и W3 означает C1-6 алкиленовую группу, которая может быть замещена), (19) -NH-CO-NH-, (20) -NH-CS-NH-, (21) -С (=NRl5)NR16- (где R15 и R16 имеют одинаковые или разные значения и представляют, каждый, атом водорода, нитрильную группу,C1-6 алкильную группу, С2-6 алкенильную группу, С3-8 циклоалкильную группу или С3-8 циклоалкенильную группу), (22) -NHC(=NH)-, (23) -O-CO-S-, (24) -S-CO-O-, (25) -ОСОО-, (26) -NHCOO-, (27) -OCONH-, (28) -СО(СН2)mО- (где m означает 0 или целое число от 1 до 6), (29) -СНОН- или (30) -СНОН (СН2)nО- (где n означает 0 или целое число от 1 до 6); R1 означает (1) атом водорода, (2) атом галогена, (3) гидроксильную группу, (4) C1-6 алкильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и нитрильной группы, (5) С2-6 алкенильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и нитрильной группы, (6) С2-6 алкинильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и нитрильной группы, (7) С3-8 циклоалкильную группу, которая может быть замещена одной или несколькими группами, выбираемыми из гидроксильной группы, атома галогена и нитрильной группы, (9) C1-6 алкокси-C1-6 алкильную группу, (10) амино-C1-6 алкильную группу, в которой атом азота может быть замещен, (11) группу формулы -N(R11)R12-(где R11 и R12 имеют одинаковые или разные значения и представляют атом водорода или C1-6 алкильную группу), (12) аралкильную группу, (13) морфолинильную группу, (14) тиоморфолинильную группу, (15) пиперидильную группу, (16) пирролидинильную группу или (17) пиперазинильную группу; и D1, D2, W1 и W2 имеют одинаковые или разные значения и представляют каждый (1) простую связь или (2) C1-6 алкиленовую цепь, которая может быть замещена; при условии, что из приведенного выше определения исключены 1-[4-циано-5-метил-4-(2-циано-5-тиенил)гексил]-4-[2-(4-фторфенокси)этил]пиперазин; 1-[4-циано-5-метил-4-(2-циано-5-тиенил)гексил]-4-[2-(3-фторфенокси)этил]пиперазин и 1-[4-циано-5-метил-4-(2-тиенил)гексил]-4-[2-(3-фторфенокси)этил]пиперазин.
30. Композиция по п.29, которая является антагонистом кальция.
31. Композиция по п.29, которая является нейронизбирательным антагонистом кальция.
32. Композиция по п.29, которая является ингибитором, по крайней мере, одного кальциевого канала P/Q-типа и N-типа.
33. Композиция по п.29, которая является средством для лечения, профилактики или улучшения состояния при заболевании, при котором эффективно ингибирующее действие в отношении, по крайней мере, одного кальциевого канала P/Q-типа и одного кальциевого канала N-типа.
34. Композиция по п.29, которая является средством, препятствующим гибели нервных клеток или защищающим нервные клетки головного мозга.
35. Композиция по п.29, которая является средством для лечения, профилактики или улучшения состояния в случае нервного заболевания.
36. Композиция по п.35, воздействующая на любое нервное заболевание, выбираемое из группы, включающей острый ишемический инсульт, кровоизлияние в мозг, инфаркт головного мозга, травму головы, гибель нервных клеток головного мозга, болезнь Альцгеймера, болезнь Паркинсона, боковой амиотрофический склероз, болезнь Хантингтона, метаболическое расстройство кровообращения головного мозга, нарушение функции головного мозга, болевой синдром, спазмы, шизофрению, мигрень, эпилепсию, маниакально-депрессивный синдром, дегенеративные нервные заболевания, ишемию головного мозга, слабоумие, вызванное СПИДом, отек мозга, состояние страха, диабетическую невропатию, слабоумие вследствие поражения сосудов головного мозга и рассеянный склероз.
37. Композиция по п.29, которая является аналгетиком.
38. Соединение по п.1, его соль или гидрат для получения антагониста кальция, нейронизбирательного антагониста кальция, ингибитора кальциевого канала P/Q-типа и/или N-типа, средства для лечения, профилактики или улучшения состояния в случае заболевания, восприимчивого к ингибированию кальциевого канала P/Q-типа и/или N-типа, средства, препятствующего гибели нервных клеток или защищающего нервные клетки головного мозга, средства для лечения, профилактики или улучшения состояния в случае нервных заболеваний или аналгетика.
39. Соединение по п.38, в котором нервное заболевание является любым заболеванием, выбираемым из группы, включающей острый ишемический инсульт, кровоизлияние в мозг, инфаркт головного мозга, травму головы, гибель нервных клеток головного мозга, болезнь Альцгеймера, болезнь Паркинсона, боковой амиотрофический склероз, болезнь Хантингтона, метаболическое расстройство кровообращения головного мозга, нарушение функции головного мозга, болевой синдром, спазмы, шизофрению, мигрень, эпилепсию, маниакально-депрессивный синдром, дегенеративные нервные заболевания, ишемию головного мозга, слабоумие, вызванное СПИДом, отек мозга, состояние страха, диабетическую невропатию, слабоумие вследствие поражения сосудов головного мозга и рассеянный склероз.
40. Способ профилактики, лечения или улучшения состояния в случае заболевания, восприимчивого к антагонизму в отношении кальция, нейронизбирательному антагонизму в отношении кальция и ингибирующему действию в отношении кальциевого канала P/Q-типа и/или N-типа, путем введения нуждающемуся субъекту фармакологически эффективного количества соединения по п.1, его соли или гидрата.
41. Способ предотвращения гибели нервных клеток или защиты нервных клеток головного мозга путем введения нуждающемуся субъекту фармакологически эффективного количества соединения по п.1, его соли или гидрата.
42. Способ профилактики, лечения или улучшения состояния в случае нервного заболевания или болевого синдрома путем введения нуждающемуся субъекту фармакологически эффективного количества соединения по п.1, его соли или гидрата.
43. Способ по п.42, в котором нервное заболевание является любым заболеванием, выбираемым из группы, включающей острый ишемический инсульт, кровоизлияние в мозг, инфаркт головного мозга, травму головы, гибель нервных клеток головного мозга, болезнь Альцгеймера, болезнь Паркинсона, боковой амиотрофический склероз, болезнь Хантингтона, метаболическое расстройство кровообращения головного мозга, нарушение функции головного мозга, болевой синдром, спазмы, шизофрению, мигрень, эпилепсию, маниакально-депрессивный синдром, дегенеративные нервные заболевания, ишемию головного мозга, слабоумие, вызванное СПИДом, отек мозга, состояние страха, диабетическую невропатию, слабоумие вследствие поражения сосудов головного мозга и рассеянный склероз.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-12176 | 2000-01-20 | ||
| JP2000012176 | 2000-01-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002122335A true RU2002122335A (ru) | 2004-01-10 |
| RU2230060C2 RU2230060C2 (ru) | 2004-06-10 |
Family
ID=18539929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002122335/04A RU2230060C2 (ru) | 2000-01-20 | 2001-01-18 | Соединения, фармацевтическая композиция, способ предотвращения гибели нервных клеток, способ профилактики |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6906072B1 (ru) |
| EP (2) | EP1818326A1 (ru) |
| KR (1) | KR20020069362A (ru) |
| CN (1) | CN1205185C (ru) |
| AT (1) | ATE362926T1 (ru) |
| AU (1) | AU779870B2 (ru) |
| BR (1) | BR0107733A (ru) |
| CA (1) | CA2398409A1 (ru) |
| DE (1) | DE60128542T2 (ru) |
| HK (1) | HK1049004A1 (ru) |
| HU (1) | HUP0204071A3 (ru) |
| IL (1) | IL150651A0 (ru) |
| MX (1) | MXPA02007035A (ru) |
| NO (1) | NO20023456L (ru) |
| NZ (1) | NZ519981A (ru) |
| RU (1) | RU2230060C2 (ru) |
| WO (1) | WO2001053258A1 (ru) |
| ZA (1) | ZA200205322B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2440985C2 (ru) * | 2006-06-19 | 2012-01-27 | Пьер Фабр Медикамент | Производные фенилпентадиеноила и их применение в качестве антагонистов par 1 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
| US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| PE20030445A1 (es) * | 2001-09-25 | 2003-07-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| US7619096B2 (en) * | 2003-06-11 | 2009-11-17 | Eli Lilly And Company | 3-Aminopyrrolidines as inhibitors of monoamine uptake |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| US7880002B2 (en) * | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| WO2006071958A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| ES2329286T3 (es) * | 2005-06-24 | 2009-11-24 | Wilex Ag | Uso de inhibidores de uroquinasa para el tratamiento y/o la prevencion de enfermedades neuropatologicas. |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| FR2890391B1 (fr) * | 2005-09-05 | 2008-06-06 | Oreal | Utilisation d'un derive de piperazine comme agent pour induire et/ou stimuler la pousse des fibres keratiniques et/ou freiner leur chute |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| US8791264B2 (en) | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| JP2010540527A (ja) * | 2007-09-25 | 2010-12-24 | アボット・ラボラトリーズ | ケモカイン受容体拮抗薬としてのオクタヒドロペンタレン化合物 |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| WO2012031383A1 (zh) | 2010-09-06 | 2012-03-15 | 中国科学院广州生物医药与健康研究院 | 酰胺类化合物 |
| WO2013149376A1 (en) | 2012-04-02 | 2013-10-10 | Abbott Laboratories | Chemokine receptor antagonists |
| PE20150775A1 (es) | 2012-10-29 | 2015-05-21 | Hoffmann La Roche | Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcio |
| EP4455145A3 (en) * | 2015-12-02 | 2025-03-12 | Astraea Therapeutics, LLC | Piperidinyl nociceptin receptor compounds |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| US11773449B2 (en) | 2017-09-01 | 2023-10-03 | The Hospital For Sick Children | Profiling and treatment of hypermutant cancer |
| RU2676701C1 (ru) * | 2017-12-01 | 2019-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Средство для сдерживания гибели нейронов при ишемическом инсульте головного мозга и способ клеточно-опосредованной генной терапии ишемического инсульта головного мозга средством сдерживания гибели нейронов при ишемическом инсульте головного мозга |
| DK3777858T3 (da) | 2018-03-30 | 2025-05-12 | Toray Industries | Middel til at hæmme stigning af intraneuronal calciumkoncentration |
| IT201800007580A1 (it) * | 2018-07-27 | 2020-01-27 | Maria Cecilia Hospital Spa | Composti 1,3,8-triazaspiro e loro uso come medicamenti |
| RU2676100C1 (ru) * | 2018-10-05 | 2018-12-26 | федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский политехнический университет Петра Великого" (ФГАОУ ВО "СПбПУ") | Применение производных пиперазина для лечения болезни Альцгеймера и деменций альцгеймеровского типа с нарушенной внутриклеточной кальциевой сигнализацией |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1305458A (ru) | 1969-02-26 | 1973-01-31 | ||
| JPS62286980A (ja) | 1986-06-05 | 1987-12-12 | Hokuriku Seiyaku Co Ltd | フエニルピペラジン誘導体 |
| JPH0745493B2 (ja) | 1987-06-24 | 1995-05-17 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| DE3784401T2 (de) * | 1986-07-31 | 1993-08-12 | Otsuka Pharma Co Ltd | Karbostyril-derivate und ihre salze, verfahren zu ihrer herstellung und diese enthaltende kardiotonische zusammensetzung. |
| JPH0696555B2 (ja) | 1986-07-31 | 1994-11-30 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| US5231105A (en) * | 1987-06-02 | 1993-07-27 | Ajinomoto Co., Inc. | Ethylamine derivatives and antihypertensives containing the same |
| JP2544939B2 (ja) * | 1987-09-01 | 1996-10-16 | 大塚製薬株式会社 | ベンゾヘテロ環誘導体 |
| JPH0283375A (ja) * | 1988-09-21 | 1990-03-23 | Dainippon Pharmaceut Co Ltd | 2−置換ピペラジニル−2−(1,2−ベンズイソキサゾール−3−イル)酢酸誘導体 |
| CA2014520C (en) | 1989-04-17 | 1996-07-16 | Fumio Suzuki | Hexitol derivatives |
| US4994460A (en) | 1989-06-01 | 1991-02-19 | Bristol-Myers Squibb Co. | Agents for treatment of brain ischemia |
| GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
| US4966472A (en) * | 1989-07-17 | 1990-10-30 | Link Larry R | Roller bushing |
| US5281601A (en) | 1989-12-12 | 1994-01-25 | Pfizer Inc. | Muscarinic receptor antagonists |
| EP0441226A1 (en) * | 1990-01-29 | 1991-08-14 | J. URIACH & CIA. S.A. | (cyanomethyl)pyridines useful as PAF antagonists |
| US5215987A (en) | 1990-04-23 | 1993-06-01 | Ortho Pharmaceutical Corporation | Substituted benzhydryl 2-hydroxypropyl piperazine derivatives |
| US5451586A (en) * | 1990-06-01 | 1995-09-19 | Pfizer Inc. | 3-amino-2-aryl quinuclidines |
| FR2676225B1 (fr) | 1991-05-03 | 1993-08-27 | Sanofi Elf | Nouveaux intermediaires pour la synthese de composes dialkylenepiperidino. |
| JPH0597673A (ja) | 1991-10-08 | 1993-04-20 | Ajinomoto Co Inc | 抗不整脈薬 |
| ES2062943B1 (es) | 1993-03-23 | 1995-11-16 | Uriach & Cia Sa J | Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas. |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| GB9526558D0 (en) | 1995-12-27 | 1996-02-28 | Fujisawa Pharmaceutical Co | Heterobicyclic derivatives |
| ES2162235T3 (es) * | 1996-01-15 | 2001-12-16 | Janssen Pharmaceutica Nv | Piridazinaminas inhibidoras de la angiogenesis. |
| IT1293804B1 (it) * | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | Diarilalchilpiperazine attive sulle basse vie urinarie |
| JP4153574B2 (ja) | 1997-09-10 | 2008-09-24 | トーアエイヨー株式会社 | 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤 |
| TWI250152B (en) * | 1998-07-21 | 2006-03-01 | Eisai Co Ltd | N,N-substituted cyclic amine compounds used as calcium antagonizer |
| US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
-
2001
- 2001-01-18 HK HK03101263.5A patent/HK1049004A1/en unknown
- 2001-01-18 HU HU0204071A patent/HUP0204071A3/hu unknown
- 2001-01-18 CA CA002398409A patent/CA2398409A1/en not_active Abandoned
- 2001-01-18 KR KR1020027009235A patent/KR20020069362A/ko not_active Abandoned
- 2001-01-18 US US10/169,837 patent/US6906072B1/en not_active Expired - Fee Related
- 2001-01-18 EP EP06016525A patent/EP1818326A1/en not_active Withdrawn
- 2001-01-18 EP EP01901413A patent/EP1254895B1/en not_active Expired - Lifetime
- 2001-01-18 NZ NZ519981A patent/NZ519981A/en unknown
- 2001-01-18 AU AU27059/01A patent/AU779870B2/en not_active Ceased
- 2001-01-18 DE DE60128542T patent/DE60128542T2/de not_active Expired - Lifetime
- 2001-01-18 IL IL15065101A patent/IL150651A0/xx unknown
- 2001-01-18 BR BR0107733-3A patent/BR0107733A/pt not_active IP Right Cessation
- 2001-01-18 MX MXPA02007035A patent/MXPA02007035A/es active IP Right Grant
- 2001-01-18 WO PCT/JP2001/000288 patent/WO2001053258A1/ja not_active Ceased
- 2001-01-18 CN CNB01803988XA patent/CN1205185C/zh not_active Expired - Fee Related
- 2001-01-18 AT AT01901413T patent/ATE362926T1/de not_active IP Right Cessation
- 2001-01-18 RU RU2002122335/04A patent/RU2230060C2/ru not_active IP Right Cessation
-
2002
- 2002-07-03 ZA ZA200205322A patent/ZA200205322B/en unknown
- 2002-07-18 NO NO20023456A patent/NO20023456L/no not_active Application Discontinuation
-
2004
- 2004-05-28 US US10/855,357 patent/US20040220193A1/en not_active Abandoned
-
2005
- 2005-09-20 US US11/229,768 patent/US20060084658A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2440985C2 (ru) * | 2006-06-19 | 2012-01-27 | Пьер Фабр Медикамент | Производные фенилпентадиеноила и их применение в качестве антагонистов par 1 |
Also Published As
| Publication number | Publication date |
|---|---|
| US6906072B1 (en) | 2005-06-14 |
| EP1254895A1 (en) | 2002-11-06 |
| US20040220193A1 (en) | 2004-11-04 |
| HUP0204071A3 (en) | 2003-07-28 |
| WO2001053258A1 (en) | 2001-07-26 |
| IL150651A0 (en) | 2003-02-12 |
| CN1395562A (zh) | 2003-02-05 |
| AU2705901A (en) | 2001-07-31 |
| EP1254895A4 (en) | 2003-01-22 |
| DE60128542D1 (de) | 2007-07-05 |
| EP1254895B1 (en) | 2007-05-23 |
| CA2398409A1 (en) | 2001-07-26 |
| MXPA02007035A (es) | 2002-12-13 |
| EP1818326A1 (en) | 2007-08-15 |
| DE60128542T2 (de) | 2008-01-31 |
| AU779870B2 (en) | 2005-02-17 |
| NZ519981A (en) | 2005-02-25 |
| NO20023456L (no) | 2002-09-20 |
| CN1205185C (zh) | 2005-06-08 |
| HK1049004A1 (en) | 2003-04-25 |
| ZA200205322B (en) | 2003-08-18 |
| ATE362926T1 (de) | 2007-06-15 |
| HUP0204071A2 (hu) | 2003-03-28 |
| NO20023456D0 (no) | 2002-07-18 |
| US20060084658A1 (en) | 2006-04-20 |
| BR0107733A (pt) | 2003-03-11 |
| RU2230060C2 (ru) | 2004-06-10 |
| KR20020069362A (ko) | 2002-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002122335A (ru) | Азотсодержащее циклическое соединение и фармацевтическая композиция, включающая указанное соединение | |
| RU2388750C2 (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| RU2205827C2 (ru) | Производное ацилпиперазинилпиримидина, способы его получения, фармацевтическая композиция | |
| RU2011115111A (ru) | Замещенные пирролидин-2-карбоксамиды | |
| RU2356893C2 (ru) | Ингибиторы фосфодиэстеразы 4 | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| RU2003121018A (ru) | Производные карбоксамида и их использование в лечении тромбоэмболических заболеваний и опухолей | |
| RU2006101053A (ru) | Производные бензамида или соль указанного производного | |
| HRP20140252T1 (hr) | Derivati imidazola kao inhibitori kazeinske kinaze | |
| RU2007143073A (ru) | Азольные соединения с нейтротерапевтической активностью | |
| RU2002101935A (ru) | Аминовые и амидные производные как лиганды для рецептора Y5 нейропептида Y, используемые для лечения ожирения и других расстройств | |
| JO2537B1 (en) | Aryl-pyridine or pyrezinate compounds replaced with heterogeneous pentagonal rings used as inhibitors of MTB proteins | |
| TW200518750A (en) | Cornea-conjunctiva disorder treating agent | |
| RU2008116313A (ru) | Диарилминсодержащие соединения, композиции и их примеение в качестве модуляторов рецепторов с-кit | |
| RU2011109339A (ru) | Новые пиррольные ингибиторы s-нитрозоглутатионредуктазы в качестве терапевтических агентов | |
| PE20081530A1 (es) | Nuevos compuestos 617 | |
| CA2473892A1 (en) | Novel quinoline derivatives | |
| AR052141A1 (es) | Compuesto amida con actividad inhibitoria de faah, un metodo para su elaboracion y agentes neuroprotectores para tratamiento o profilaxis de desordenes cerebrovasculares. | |
| NZ600716A (en) | Substituted isoquinolinones and quinazolinones | |
| AR045360A1 (es) | Piperazina con grupo fenilo or-sustituido y su uso como inhibidor glyt1 | |
| RU2004115737A (ru) | Соединение хинолина | |
| RU2005104819A (ru) | Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина | |
| PE20081783A1 (es) | Nuevas 2-aminooxazolinas como ligandos de taar1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080119 |